- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01563913
Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids (RLID-PD)
Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most patients with Parkinson disease(PD) as a consequence of chronic use of the most effective symptomatic drug, levodopa (LD). LID can range from subtle and unobtrusive to marked and disabling. There are surprisingly few treatments for LID, including amantadine and deep brain stimulation. In many instances, amantadine is either poorly tolerated, or provides inadequate benefit, and only a small minority are appropriate candidates for surgery. Given the finding that docosahexanoic acid (the most abundant omega-3 fatty acid in the brain), delays the onset and reduces the severity of dyskinesia in two different animal models of LID, a trial of docosahexanoic acid (DHA) in PD subjects about to start LD as part of their drug regimen, to prevent or slow the progression of LID is warranted.
Prior to embarking on a large trial, preliminary data about safety and tolerability of DHA in PD subjects is needed, and collection of this data is the primary outcome of this pilot project proposal. 40 subjects who have not yet used levodopa, but are about to begin it will be randomized to daily DHA or placebo. Safety laboratory testing, adverse event monitoring, DHA plasma and CSF levels as well as compliance/subject retention will be outcomes collected.
In addition, preliminary data about modification of incidence rates will be collected and compared between the two treatment groups. This information will aid in calculating an appropriate sample size and treatment period for a larger definitive future study.
Dyskinesia manifests overwhelmingly when plasma levodopa levels are high enough to cause anti-parkinsonian benefits, and lessens or stops when levodopa levels drop below a threshold. Thus, the subject's dyskinesia measurements must occur during a levodopa administration period. Dyskinesia measurement will occur during a two-hour levodopa cycle administered to subjects at weeks 0, 6, 24, 52, 76. It is expected that a good proportion of subjects will manifest dyskinesia within the two-year observation period, as previous studies using the most objective means to measure dyskinesia report incidence rates of 67% or greater within the first year of levodopa use. An instrument to measure dyskinesia developed by this center will be used as an additional outcome, and is expected to measure dyskinesia more accurately and with greater sensitivity than the gold standard methods of clinical rating scales.
By conclusion of this pilot project, the safety and tolerability, subject retention and compliance, plasma/CSF levels of DHA administration will be determined. Trends in dyskinesia development may be measured. This will provide the needed background information to proceed with a future larger trial of DHA to prevent dyskinesia in PD.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- VA Portland Health Care System, Portland, OR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with Parkinsons disease
- No levodopa (Sinemet) treatment or prior exposure to levodopa
Exclusion Criteria:
- Prior exposure to levodopa
- Unable to stand for 1 minute without aid
- Sensory deficits on feet
- Significant cognitive impairment
- Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone, tetrabenazine, metoclopramide, dronabinol)
- Current fish oil or lutein supplementation
- Allergy to soy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm 2
Placebo
|
Sugar Pill, taken for 1.5 years
Other Names:
|
Experimental: Arm 1
Docosahexaenoic Acid (DHA)
|
Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of DHA - Change in Blood ng/dL Levels
Time Frame: baseline and 1.5 years
|
Therapeutic level monitoring will be accomplished by analyzing blood levels for DHA.
|
baseline and 1.5 years
|
Efficacy of DHA - Number of Participants With An Abnormal Safety Lab (CBC)
Time Frame: Year 1
|
This study is seeking to determine the safety/efficacy of DHA in Parkinson's disease patients.
The safety/efficacy of DHA will be determined using periodic safety lab information.
Safety labs for complete blood count (CBC) were performed at each inpatient visit, reviewed by the PI, and marked as normal or abnormal.
|
Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forceplate Measured Dyskinesia
Time Frame: baseline and 1.5 years
|
Dyskinesia are abnormal movements caused by levodopa.
These abnormal movements will be measured with a forceplate (a device that is similar to a door mat).
Dyskinesia will be examined at all inpatient visits and area under the curves will be compared with a clinical rating scale to measure the development of dyskinesia after starting levodopa therapy.
|
baseline and 1.5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kathryn Anne Chung, MD, VA Portland Health Care System, Portland, OR
Publications and helpful links
General Publications
- Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91. doi: 10.1056/NEJM200005183422004.
- Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002 Jun;51(6):686-93. doi: 10.1002/ana.10189.
- Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001 Sep;36(9):945-59. doi: 10.1007/s11745-001-0805-6.
- Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; Trial Study Group. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005 Dec;12(12):956-63. doi: 10.1111/j.1468-1331.2005.01096.x.
- Chung KA, Lobb BM, Nutt JG, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord. 2010 Apr 15;25(5):602-8. doi: 10.1002/mds.22856.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-006-11S
- 2907 (Other Identifier: Portland VA Medical Center)
- 8012 (Oregon Health & Science University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Docosahexaenoic Acid (DHA)
-
Pontificia Universidad Catolica de ChileUniversity of Chile; Laboratorio Gynopharm - CFRUnknownPremature Birth | Fetal Growth Retardation | Preeclampsia | StillbirthChile
-
University of Kansas Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedUse and Dose of Prenatal DHA SupplementationUnited States
-
Texas Christian UniversityCompleted
-
National Institute on Alcohol Abuse and Alcoholism...CompletedHealthyUnited States
-
University of MilanCompleted
-
University of CincinnatiCompletedHealthy | AttentionUnited States
-
Campus Bio-Medico UniversityIRCCS San Raffaele; DSM Nutritional Products, Inc.; Pharmanutra s.r.l.Completed
-
University of Kansas Medical CenterOhio State University; Nationwide Children's Hospital; University of CincinnatiCompleted
-
Universidad de GranadaPuleva BiotechCompletedInflammation | Oxidative Stress | Infant DevelopmentSpain